We present the case of a 19-year-old male athlete with protein C deficiency who developed proximal deep venous thrombosis and pulmonary embolism while abusing anabolic-androgenic steroids. Anabolicandrogenic steroids have been reported to have anticoagulatory and profibrinolytic effects in patients with protein C deficiency. Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin. The net effect of anabolic-androgenic steroids on the haemostatic system may change from antithrombotic to prothrombotic in male abusers of anabolic steroids with protein C deficiency.
Introduction
Cardiovascular events have been reported repeatedly in male athletes abusing anabolic-androgenic steroids (AAS) 1 whereas very little is known about the interaction of AAS and the haemostatic system. Some reports indicate an accelerated activation of the haemostatic system as indicated by an increased generation of both thrombin and plasmin, 2 causing venous thromboembolism such as cerebral vein thrombosis. [3] [4] [5] [6] [7] Other reports have proposed an anticoagulant effect of AAS in patients with congenital and acquired protein C 8, 9 and protein S deficiency 10 or by activation of the fibrinolytic system. 11 We present the case of a patient with protein C deficiency who developed proximal deep venous thrombosis (DVT) and pulmonary embolism (PE) while abusing AAS.
Case History
A 19-year-old nonsmoking man presented to us in September 2003 with a swelling of the left leg. The patient was otherwise healthy, and there was no history for venous thromboembolism in the patient's family. However, protein C levels were not obtained from the patient's relatives. Phlebography revealed a thrombosis of the great saphenous vein (GSV) without signs for DVT. Colour Duplex scan of the left leg showed a thrombophlebitis of the GSV below the knee ( Figure 1 ). Computed tomography (CT) of the abdomen showed no thrombosis of the iliocaval vein segments. He was treated with lowmolecular-weight heparin (LMWH) Enoxaparin sodium, 80 mg, subcutaneously twice daily for 2 weeks but failed to attend the planned follow-up appointments.
In November 2005, he experienced shortness of breath on exertion, chest pain, fever, and haemoptysis. Respiratory rate at rest was 30/min and saturation was 93% with oxygen delivered through nose grime. Computed tomography of the thorax showed bilateral PE of the lower lobe artery with parenchymal changes and right-sided pleural effusion ( Figure 2 ). Antibiotic treatment was started and the pleural effusion was drained. Colour Duplex scan showed DVT, involving the left common femoral vein, femoral vein, deep femoral vein, and popliteal vein. On echocardiography, the right ventricle strain pattern was moderately increased with pulmonary arterial pressure of 35 mm Hg. Low-molecular-weight heparin treatment was started in the evening with dalteparin sodium, at a dose of 18 000 IU daily and 12.5 mg warfarin. The following morning, he complained of nausea and headache. Computed tomography of the brain showed a subdural hematoma, which was treated conservatively. The international normalized ratio (INR) was 3:7, plasma protein C measured at 2 time points with and without warfarin treatment was below 0.10. A third measurement of protein C levels 2 years after the initial event under stable INR values confirmed a significant protein C deficiency. Other laboratory analyses for thrombocytes, antithrombin, protein S, homocysteine, anticardiolipin antibodies, prothrombin gene mutation, activated protein C resistance, and lupus anticoagulant were all within normal limits at several times during the initial treatment and during follow-up. He received 1 dosage of Prothromplex 2500 IU and 5 mg of vitamin K. The patient was given dalteparin sodium, at a prophylaxis dose of 5000 IU daily through 1 week, and then increased to 7500 IU. A retrievable inferior vena cava (IVC) filter was deployed in the infrarenal IVC to prevent further PE. The patient now admitted taking AAS (Ryssfemmor, tablets of 5 mg) in large amounts, ''usually a hand full,'' since at least 2001, with the purpose to achieve a better body fitness.
He was discharged after 2 weeks but readmitted 5 days later because of pain and swelling of both legs. Duplex scan and abdominal CT displayed a progression of the right-sided thrombosis to the external and common iliac vein, the IVC. The IVC filter was thrombosed and the top of the thrombosis was located just below the renal veins ( Figure 3) .
The dalteparin sodium dose was changed to 7500 IU subcutaneously twice daily, and he was advised to wear graded compression stockings and to position his legs in a high position whenever possible. Low-molecular-weight heparin therapy was discontinued after 4 weeks and warfarin treatment was initiated. The IVC filter was left in place as a permanent one. The swelling of the legs reduced gradually. Follow-up with the last visit in September 2007 has been uneventful, besides a moderate postthrombotic syndrome.
Discussion
Although several studies report acute cardiovascular events correlated with the use of AAS, 1 there are still considerable controversies about the mechanisms of AAS and their interaction with the haemostatic system. Some reports have proposed an anticoagulant effect of AAS in patients with congenital and acquired protein C 8, 9 and protein S deficiency 10 ; other reports indicate an accelerated activation of the haemostatic system. 2 Liljeqvist et al recently published a case report about the probable association between anabolic steroid abuse and the occurrence of PE. 12 Our patient developed a subdural hematoma at the initial anticoagulation therapy, which may have developed because of anticoagulation with a supratherapeutic INR value. However, other mechanisms may be involved such as preexisting abnormalities in the cerebral vein or isolated intracranial hypertension during AAS. 13, 14 Despite the reported protective anticoagulatory and profibrinolytic effects of AAS in patients having protein C deficiency, 8, 9 our patient developed repeated venous thromboembolism despite treatment with LMWH. One contributing factor to the massive iliocaval thrombosis might have been the placement of an IVC filter. In addition, anabolic steroids may induce a thrombotic tendency through alterations in other haemostatic mechanisms or changes in lipid fractions 15 or similar to estrogen-based therapies 16 and so the etiology of the thrombotic events remains unclear.
In male abusers of anabolic steroids, the net effect on the haemostatic system may change from antithrombotic to prothrombotic. There might be an individual threshold dose above which thrombogenic effects on platelets and vasomotion may overcome the profibrinolytic effects on plasminogen activator inhibitor. 17 Future studies on the relation between anabolic steroids and protein C deficiency are needed.
